FOXA1 mutations dysregulated estrogen-ER activity (Figure 2B) and were associated with worse outcome for metastatic ER + breast cancer (Hurtado et al., 2011; Arruabarrena-Aristorena et al., 2020). Here, FOXA1 is linked to breast cancer.